Recombinant plant-derived pharmaceutical proteins: current technical and economic bottlenecks

@article{Sabalza2014RecombinantPP,
  title={Recombinant plant-derived pharmaceutical proteins: current technical and economic bottlenecks},
  author={Maite Sabalza and Paul Christou and Teresa Capell},
  journal={Biotechnology Letters},
  year={2014},
  volume={36},
  pages={2367-2379}
}
Molecular pharming is a cost-effective platform for the production of recombinant proteins in plants. Although the biopharmaceutical industry still relies on a small number of standardized fermentation-based technologies for the production of recombinant proteins there is now a greater awareness of the advantages of molecular pharming particularly in niche markets. Here we discuss some of the technical, economic and regulatory barriers that constrain the clinical development and… CONTINUE READING
Highly Cited
This paper has 88 citations. REVIEW CITATIONS

From This Paper

Figures, tables, and topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

89 Citations

0204020152016201720182019
Citations per Year
Semantic Scholar estimates that this publication has 89 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 97 references

Transgenic plants in the biopharmaceutical market.

Expert opinion on emerging drugs • 2005
View 5 Excerpts
Highly Influenced

Inhibiting sexual transmission of HIV-1 infection

Nature Reviews Microbiology • 2003
View 1 Excerpt
Highly Influenced

Similar Papers

Loading similar papers…